File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Review of the Varilrix™ varicella vaccine

TitleReview of the Varilrix™ varicella vaccine
Authors
Issue Date2005
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=6
Citation
Expert Review Of Vaccines, 2005, v. 4 n. 5, p. 629-643 How to Cite?
AbstractVaricella zoster virus causes an acute infection that affects most children globally, but the age of infection can be greater in residents of tropical areas. It has generally been considered a mild disease, although there are accumulating data to show that it can cause significant morbidity and mortality in immunocompetent as well as immunocompromised children and adults. Oka-strain live attenuated varicella vaccines were developed in the 1970s. Varilrix™ developed by GlaxoSmithKline Biologicals (Rixensart, Belgium), is one of the vaccines produced and marketed in over 80 countries. Similar to the other Oka-strain vaccines, Varilrix is safe, immunogenic and efficacious in both immunocompromised and immunocompetent children and adults. © 2005 Future Drugs Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/170350
ISSN
2015 Impact Factor: 4.222
2015 SCImago Journal Rankings: 1.785
References

 

DC FieldValueLanguage
dc.contributor.authorChiu, SSen_US
dc.contributor.authorLau, YLen_US
dc.date.accessioned2012-10-30T06:07:43Z-
dc.date.available2012-10-30T06:07:43Z-
dc.date.issued2005en_US
dc.identifier.citationExpert Review Of Vaccines, 2005, v. 4 n. 5, p. 629-643en_US
dc.identifier.issn1476-0584en_US
dc.identifier.urihttp://hdl.handle.net/10722/170350-
dc.description.abstractVaricella zoster virus causes an acute infection that affects most children globally, but the age of infection can be greater in residents of tropical areas. It has generally been considered a mild disease, although there are accumulating data to show that it can cause significant morbidity and mortality in immunocompetent as well as immunocompromised children and adults. Oka-strain live attenuated varicella vaccines were developed in the 1970s. Varilrix™ developed by GlaxoSmithKline Biologicals (Rixensart, Belgium), is one of the vaccines produced and marketed in over 80 countries. Similar to the other Oka-strain vaccines, Varilrix is safe, immunogenic and efficacious in both immunocompromised and immunocompetent children and adults. © 2005 Future Drugs Ltd.en_US
dc.languageengen_US
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=6en_US
dc.relation.ispartofExpert Review of Vaccinesen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshChickenpox - Prevention & Controlen_US
dc.subject.meshChickenpox Vaccineen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshHerpes Zoster - Prevention & Controlen_US
dc.subject.meshHerpesvirus 3, Human - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunization Scheduleen_US
dc.subject.meshImmunocompromised Hosten_US
dc.subject.meshInfanten_US
dc.subject.meshLeukemia - Immunologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNephrotic Syndrome - Immunologyen_US
dc.subject.meshProduct Surveillance, Postmarketingen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshVaccinationen_US
dc.titleReview of the Varilrix™ varicella vaccineen_US
dc.typeArticleen_US
dc.identifier.emailChiu, SS:ssschiu@hkucc.hku.hken_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityChiu, SS=rp00421en_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1586/14760584.4.5.629en_US
dc.identifier.pmid16221065-
dc.identifier.scopuseid_2-s2.0-27444437402en_US
dc.identifier.hkuros109335-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27444437402&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume4en_US
dc.identifier.issue5en_US
dc.identifier.spage629en_US
dc.identifier.epage643en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChiu, SS=7202291500en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats